P-1707. A Comparative Analysis of Clindamycin versus Linezolid as Adjunctive Anti-toxin Therapy for Invasive Group A Streptococcal Infections Article Swipe
Megha Jagannathan
,
Tamara Jordan
,
Daniel Kinsey
,
Rachel M. Kenney
,
Michael P. Veve
,
Anita Shallal
,
Geehan Suleyman
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofae631.1873
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/ofid/ofae631.1873
Background Group A Streptococcus (GAS) is an important pathogen that can cause life-threatening disease. Clindamycin (DA) and linezolid (LZD) have been used as adjunctive antitoxin (AT) therapy in high-inoculum GAS infections to inhibit bacterial protein synthesis. However, there is concern about DA efficacy in the era of increasing DA resistance, where LZD may have a role. We evaluated outcomes of patients with invasive GAS infection who received DA or LZD.Table 1.Comorbidities and clinical syndromes of patients receiving Clindamycin vs. Linezolid (n=158) Methods Retrospective cohort study comparing patients with positive blood cultures (BC) for GAS from June 2013-Dec 2023 treated with DA or LZD ≥ 48 hours. We identified patients using a data query for positive BC for GAS through Microsoft SQL. Patients aged < 18 years, or those with polymicrobial bacteremia, receipt of both AT therapies, incomplete data, or enrolled in hospice/died within 48-hours of admission were excluded. Collected variables included: demographics, infection characteristics, microbiologic data, adjunct therapy (surgical, immunoglobulin), and clinical outcomes (treatment-associated adverse events, 30-day all-cause mortality and infection-related readmission).Table 2.Severity of illness and adjunctive therapies of patients receiving Clindamycin vs Linezolid (n=158) Results 158 patients were included; 117 patients received DA and 41 patients LZD. Baseline characteristics were similar among groups except for chronic kidney disease, which was more common in the LZD group (Table 1). The most common clinical syndrome accompanying bacteremia in both groups was abscess/cellulitis; bone and joint infection was more prevalent in the LZD group. 55 (33.5%) of GAS isolates were DA resistant. There was no significant difference in severity of illness, surgical interventions, or duration of therapy between the two groups (Table 2). Duration of bacteremia was significantly longer in the LZD group. There was no significant difference in readmission (10.3% vs 12.2%, p=0.77) or all-cause mortality within 30 days (17.1% vs 7.3%, p=0.13) in the DA versus LZD groups. Treatment-associated adverse events were low across both groups [Figure 1]. Conclusion Despite increasing DA resistance at our facility, there was no significant difference in outcomes between patients treated with LZD vs DA plus standard therapy, consistent with prior literature. Further studies are needed to determine optimal therapy for invasive GAS. Disclosures Rachel M. Kenney, PharmD, BCIDP, Medtronic Inc: Spouse is an employee, stockholder
Related Topics
Concepts
Linezolid
Medicine
Clindamycin
Internal medicine
Antibiotics
Vancomycin
Microbiology
Staphylococcus aureus
Bacteria
Genetics
Biology
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ofid/ofae631.1873
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4406942959
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4406942959Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ofid/ofae631.1873Digital Object Identifier
- Title
-
P-1707. A Comparative Analysis of Clindamycin versus Linezolid as Adjunctive Anti-toxin Therapy for Invasive Group A Streptococcal InfectionsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-01-29Full publication date if available
- Authors
-
Megha Jagannathan, Tamara Jordan, Daniel Kinsey, Rachel M. Kenney, Michael P. Veve, Anita Shallal, Geehan SuleymanList of authors in order
- Landing page
-
https://doi.org/10.1093/ofid/ofae631.1873Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1093/ofid/ofae631.1873Direct OA link when available
- Concepts
-
Linezolid, Medicine, Clindamycin, Internal medicine, Antibiotics, Vancomycin, Microbiology, Staphylococcus aureus, Bacteria, Genetics, BiologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4406942959 |
|---|---|
| doi | https://doi.org/10.1093/ofid/ofae631.1873 |
| ids.doi | https://doi.org/10.1093/ofid/ofae631.1873 |
| ids.openalex | https://openalex.org/W4406942959 |
| fwci | 0.0 |
| type | article |
| title | P-1707. A Comparative Analysis of Clindamycin versus Linezolid as Adjunctive Anti-toxin Therapy for Invasive Group A Streptococcal Infections |
| biblio.issue | Supplement_1 |
| biblio.volume | 12 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11153 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9975000023841858 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2739 |
| topics[0].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[0].display_name | Streptococcal Infections and Treatments |
| topics[1].id | https://openalex.org/T10195 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9922999739646912 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | Antimicrobial Resistance in Staphylococcus |
| topics[2].id | https://openalex.org/T12167 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9828000068664551 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1308 |
| topics[2].subfield.display_name | Clinical Biochemistry |
| topics[2].display_name | Bacterial Identification and Susceptibility Testing |
| is_xpac | False |
| apc_list.value | 3064 |
| apc_list.currency | USD |
| apc_list.value_usd | 3064 |
| apc_paid.value | 3064 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3064 |
| concepts[0].id | https://openalex.org/C2781414143 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9145280718803406 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q411377 |
| concepts[0].display_name | Linezolid |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8959791660308838 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2777458120 |
| concepts[2].level | 3 |
| concepts[2].score | 0.841884195804596 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q422273 |
| concepts[2].display_name | Clindamycin |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.39113157987594604 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C501593827 |
| concepts[4].level | 2 |
| concepts[4].score | 0.34175539016723633 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[4].display_name | Antibiotics |
| concepts[5].id | https://openalex.org/C2778980435 |
| concepts[5].level | 4 |
| concepts[5].score | 0.21577823162078857 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q424027 |
| concepts[5].display_name | Vancomycin |
| concepts[6].id | https://openalex.org/C89423630 |
| concepts[6].level | 1 |
| concepts[6].score | 0.1901766061782837 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[6].display_name | Microbiology |
| concepts[7].id | https://openalex.org/C2779489039 |
| concepts[7].level | 3 |
| concepts[7].score | 0.10668110847473145 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q188121 |
| concepts[7].display_name | Staphylococcus aureus |
| concepts[8].id | https://openalex.org/C523546767 |
| concepts[8].level | 2 |
| concepts[8].score | 0.05080023407936096 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q10876 |
| concepts[8].display_name | Bacteria |
| concepts[9].id | https://openalex.org/C54355233 |
| concepts[9].level | 1 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[9].display_name | Genetics |
| concepts[10].id | https://openalex.org/C86803240 |
| concepts[10].level | 0 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[10].display_name | Biology |
| keywords[0].id | https://openalex.org/keywords/linezolid |
| keywords[0].score | 0.9145280718803406 |
| keywords[0].display_name | Linezolid |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8959791660308838 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/clindamycin |
| keywords[2].score | 0.841884195804596 |
| keywords[2].display_name | Clindamycin |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.39113157987594604 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/antibiotics |
| keywords[4].score | 0.34175539016723633 |
| keywords[4].display_name | Antibiotics |
| keywords[5].id | https://openalex.org/keywords/vancomycin |
| keywords[5].score | 0.21577823162078857 |
| keywords[5].display_name | Vancomycin |
| keywords[6].id | https://openalex.org/keywords/microbiology |
| keywords[6].score | 0.1901766061782837 |
| keywords[6].display_name | Microbiology |
| keywords[7].id | https://openalex.org/keywords/staphylococcus-aureus |
| keywords[7].score | 0.10668110847473145 |
| keywords[7].display_name | Staphylococcus aureus |
| keywords[8].id | https://openalex.org/keywords/bacteria |
| keywords[8].score | 0.05080023407936096 |
| keywords[8].display_name | Bacteria |
| language | en |
| locations[0].id | doi:10.1093/ofid/ofae631.1873 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735126445 |
| locations[0].source.issn | 2328-8957 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2328-8957 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Open Forum Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Open Forum Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/ofid/ofae631.1873 |
| locations[1].id | pmh:oai:pubmedcentral.nih.gov:11778851 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S2764455111 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed Central |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | other-oa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/other-oa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Open Forum Infect Dis |
| locations[1].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11778851 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5011233950 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Megha Jagannathan |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I2803043754 |
| authorships[0].affiliations[0].raw_affiliation_string | Henry Ford Hospital , Detroit, Michigan |
| authorships[0].institutions[0].id | https://openalex.org/I2803043754 |
| authorships[0].institutions[0].ror | https://ror.org/0193sb042 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I154057602, https://openalex.org/I2803043754 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Henry Ford Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Megha Jagannathan |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Henry Ford Hospital , Detroit, Michigan |
| authorships[1].author.id | https://openalex.org/A5074349103 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-8667-9461 |
| authorships[1].author.display_name | Tamara Jordan |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2803043754 |
| authorships[1].affiliations[0].raw_affiliation_string | Henry Ford Hospital , Detroit, Michigan |
| authorships[1].institutions[0].id | https://openalex.org/I2803043754 |
| authorships[1].institutions[0].ror | https://ror.org/0193sb042 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I154057602, https://openalex.org/I2803043754 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Henry Ford Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Tamara Jordan |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Henry Ford Hospital , Detroit, Michigan |
| authorships[2].author.id | https://openalex.org/A5109022719 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Daniel Kinsey |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2803043754 |
| authorships[2].affiliations[0].raw_affiliation_string | Henry Ford Hospital , Detroit, Michigan |
| authorships[2].institutions[0].id | https://openalex.org/I2803043754 |
| authorships[2].institutions[0].ror | https://ror.org/0193sb042 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I154057602, https://openalex.org/I2803043754 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Henry Ford Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Daniel Kinsey |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Henry Ford Hospital , Detroit, Michigan |
| authorships[3].author.id | https://openalex.org/A5009039786 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3696-2204 |
| authorships[3].author.display_name | Rachel M. Kenney |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2803043754 |
| authorships[3].affiliations[0].raw_affiliation_string | Henry Ford Hospital , Detroit, Michigan |
| authorships[3].institutions[0].id | https://openalex.org/I2803043754 |
| authorships[3].institutions[0].ror | https://ror.org/0193sb042 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I154057602, https://openalex.org/I2803043754 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Henry Ford Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Rachel M Kenney |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Henry Ford Hospital , Detroit, Michigan |
| authorships[4].author.id | https://openalex.org/A5021111881 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5967-5211 |
| authorships[4].author.display_name | Michael P. Veve |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I154057602 |
| authorships[4].affiliations[0].raw_affiliation_string | Henry Ford Health , Detroit, Michigan |
| authorships[4].institutions[0].id | https://openalex.org/I154057602 |
| authorships[4].institutions[0].ror | https://ror.org/02kwnkm68 |
| authorships[4].institutions[0].type | nonprofit |
| authorships[4].institutions[0].lineage | https://openalex.org/I154057602 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Henry Ford Health System |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Michael Veve |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Henry Ford Health , Detroit, Michigan |
| authorships[5].author.id | https://openalex.org/A5047366001 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-1940-3622 |
| authorships[5].author.display_name | Anita Shallal |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I154057602 |
| authorships[5].affiliations[0].raw_affiliation_string | Henry Ford Health , Detroit, Michigan |
| authorships[5].institutions[0].id | https://openalex.org/I154057602 |
| authorships[5].institutions[0].ror | https://ror.org/02kwnkm68 |
| authorships[5].institutions[0].type | nonprofit |
| authorships[5].institutions[0].lineage | https://openalex.org/I154057602 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Henry Ford Health System |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Anita Shallal |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Henry Ford Health , Detroit, Michigan |
| authorships[6].author.id | https://openalex.org/A5057735608 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-5630-0104 |
| authorships[6].author.display_name | Geehan Suleyman |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I154057602 |
| authorships[6].affiliations[0].raw_affiliation_string | Henry Ford Health , Detroit, Michigan |
| authorships[6].institutions[0].id | https://openalex.org/I154057602 |
| authorships[6].institutions[0].ror | https://ror.org/02kwnkm68 |
| authorships[6].institutions[0].type | nonprofit |
| authorships[6].institutions[0].lineage | https://openalex.org/I154057602 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Henry Ford Health System |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Geehan Suleyman |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Henry Ford Health , Detroit, Michigan |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1093/ofid/ofae631.1873 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | P-1707. A Comparative Analysis of Clindamycin versus Linezolid as Adjunctive Anti-toxin Therapy for Invasive Group A Streptococcal Infections |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11153 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9975000023841858 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2739 |
| primary_topic.subfield.display_name | Public Health, Environmental and Occupational Health |
| primary_topic.display_name | Streptococcal Infections and Treatments |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W3092766063 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/ofid/ofae631.1873 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735126445 |
| best_oa_location.source.issn | 2328-8957 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2328-8957 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Open Forum Infectious Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Open Forum Infectious Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ofid/ofae631.1873 |
| primary_location.id | doi:10.1093/ofid/ofae631.1873 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735126445 |
| primary_location.source.issn | 2328-8957 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2328-8957 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Open Forum Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Open Forum Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/ofid/ofae631.1873 |
| publication_date | 2025-01-29 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.A | 3 |
| abstract_inverted_index.a | 55, 111 |
| abstract_inverted_index.18 | 125 |
| abstract_inverted_index.30 | 297 |
| abstract_inverted_index.41 | 196 |
| abstract_inverted_index.48 | 105 |
| abstract_inverted_index.55 | 243 |
| abstract_inverted_index.AT | 135 |
| abstract_inverted_index.BC | 116 |
| abstract_inverted_index.DA | 42, 49, 68, 101, 194, 249, 305, 322, 340 |
| abstract_inverted_index.M. | 361 |
| abstract_inverted_index.We | 57, 107 |
| abstract_inverted_index.an | 7, 369 |
| abstract_inverted_index.as | 23 |
| abstract_inverted_index.at | 324 |
| abstract_inverted_index.in | 28, 44, 141, 214, 227, 239, 256, 278, 287, 303, 332 |
| abstract_inverted_index.is | 6, 39, 368 |
| abstract_inverted_index.no | 253, 284, 329 |
| abstract_inverted_index.of | 47, 60, 75, 133, 145, 174, 179, 245, 258, 264, 273 |
| abstract_inverted_index.or | 69, 102, 127, 139, 262, 293 |
| abstract_inverted_index.to | 32, 352 |
| abstract_inverted_index.vs | 183, 290, 300, 339 |
| abstract_inverted_index.1). | 219 |
| abstract_inverted_index.117 | 191 |
| abstract_inverted_index.158 | 187 |
| abstract_inverted_index.1]. | 318 |
| abstract_inverted_index.2). | 271 |
| abstract_inverted_index.GAS | 30, 64, 94, 118, 246 |
| abstract_inverted_index.LZD | 52, 103, 216, 241, 280, 307, 338 |
| abstract_inverted_index.The | 220 |
| abstract_inverted_index.and | 17, 72, 161, 170, 176, 195, 233 |
| abstract_inverted_index.are | 350 |
| abstract_inverted_index.can | 11 |
| abstract_inverted_index.era | 46 |
| abstract_inverted_index.for | 93, 114, 117, 206, 356 |
| abstract_inverted_index.low | 313 |
| abstract_inverted_index.may | 53 |
| abstract_inverted_index.our | 325 |
| abstract_inverted_index.the | 45, 215, 240, 267, 279, 304 |
| abstract_inverted_index.two | 268 |
| abstract_inverted_index.vs. | 79 |
| abstract_inverted_index.was | 211, 230, 236, 252, 275, 283, 328 |
| abstract_inverted_index.who | 66 |
| abstract_inverted_index.≥ | 104 |
| abstract_inverted_index.(AT) | 26 |
| abstract_inverted_index.(BC) | 92 |
| abstract_inverted_index.(DA) | 16 |
| abstract_inverted_index.2023 | 98 |
| abstract_inverted_index.GAS. | 358 |
| abstract_inverted_index.Inc: | 366 |
| abstract_inverted_index.June | 96 |
| abstract_inverted_index.LZD. | 198 |
| abstract_inverted_index.SQL. | 121 |
| abstract_inverted_index.aged | 123 |
| abstract_inverted_index.been | 21 |
| abstract_inverted_index.bone | 232 |
| abstract_inverted_index.both | 134, 228, 315 |
| abstract_inverted_index.data | 112 |
| abstract_inverted_index.days | 298 |
| abstract_inverted_index.from | 95 |
| abstract_inverted_index.have | 20, 54 |
| abstract_inverted_index.more | 212, 237 |
| abstract_inverted_index.most | 221 |
| abstract_inverted_index.plus | 341 |
| abstract_inverted_index.that | 10 |
| abstract_inverted_index.used | 22 |
| abstract_inverted_index.were | 147, 189, 201, 248, 312 |
| abstract_inverted_index.with | 62, 88, 100, 129, 337, 345 |
| abstract_inverted_index.(GAS) | 5 |
| abstract_inverted_index.(LZD) | 19 |
| abstract_inverted_index.7.3%, | 301 |
| abstract_inverted_index.Group | 2 |
| abstract_inverted_index.There | 251, 282 |
| abstract_inverted_index.about | 41 |
| abstract_inverted_index.among | 203 |
| abstract_inverted_index.blood | 90 |
| abstract_inverted_index.cause | 12 |
| abstract_inverted_index.data, | 138, 156 |
| abstract_inverted_index.group | 217 |
| abstract_inverted_index.joint | 234 |
| abstract_inverted_index.prior | 346 |
| abstract_inverted_index.query | 113 |
| abstract_inverted_index.role. | 56 |
| abstract_inverted_index.study | 85 |
| abstract_inverted_index.there | 38, 327 |
| abstract_inverted_index.those | 128 |
| abstract_inverted_index.using | 110 |
| abstract_inverted_index.where | 51 |
| abstract_inverted_index.which | 210 |
| abstract_inverted_index.(10.3% | 289 |
| abstract_inverted_index.(17.1% | 299 |
| abstract_inverted_index.(Table | 218, 270 |
| abstract_inverted_index.12.2%, | 291 |
| abstract_inverted_index.30-day | 167 |
| abstract_inverted_index.BCIDP, | 364 |
| abstract_inverted_index.Rachel | 360 |
| abstract_inverted_index.Spouse | 367 |
| abstract_inverted_index.across | 314 |
| abstract_inverted_index.cohort | 84 |
| abstract_inverted_index.common | 213, 222 |
| abstract_inverted_index.events | 311 |
| abstract_inverted_index.except | 205 |
| abstract_inverted_index.group. | 242, 281 |
| abstract_inverted_index.groups | 204, 229, 269, 316 |
| abstract_inverted_index.hours. | 106 |
| abstract_inverted_index.kidney | 208 |
| abstract_inverted_index.longer | 277 |
| abstract_inverted_index.needed | 351 |
| abstract_inverted_index.versus | 306 |
| abstract_inverted_index.within | 143, 296 |
| abstract_inverted_index.years, | 126 |
| abstract_inverted_index.(33.5%) | 244 |
| abstract_inverted_index.(n=158) | 81, 185 |
| abstract_inverted_index.Despite | 320 |
| abstract_inverted_index.Further | 348 |
| abstract_inverted_index.Kenney, | 362 |
| abstract_inverted_index.Methods | 82 |
| abstract_inverted_index.PharmD, | 363 |
| abstract_inverted_index.Results | 186 |
| abstract_inverted_index.[Figure | 317 |
| abstract_inverted_index.adjunct | 157 |
| abstract_inverted_index.adverse | 165, 310 |
| abstract_inverted_index.between | 266, 334 |
| abstract_inverted_index.chronic | 207 |
| abstract_inverted_index.concern | 40 |
| abstract_inverted_index.events, | 166 |
| abstract_inverted_index.groups. | 308 |
| abstract_inverted_index.illness | 175 |
| abstract_inverted_index.inhibit | 33 |
| abstract_inverted_index.optimal | 354 |
| abstract_inverted_index.p=0.13) | 302 |
| abstract_inverted_index.p=0.77) | 292 |
| abstract_inverted_index.protein | 35 |
| abstract_inverted_index.receipt | 132 |
| abstract_inverted_index.similar | 202 |
| abstract_inverted_index.studies | 349 |
| abstract_inverted_index.therapy | 27, 158, 265, 355 |
| abstract_inverted_index.through | 119 |
| abstract_inverted_index.treated | 99, 336 |
| abstract_inverted_index.&lt; | 124 |
| abstract_inverted_index.2013-Dec | 97 |
| abstract_inverted_index.48-hours | 144 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Baseline | 199 |
| abstract_inverted_index.Duration | 272 |
| abstract_inverted_index.However, | 37 |
| abstract_inverted_index.Patients | 122 |
| abstract_inverted_index.clinical | 73, 162, 223 |
| abstract_inverted_index.cultures | 91 |
| abstract_inverted_index.disease, | 209 |
| abstract_inverted_index.disease. | 14 |
| abstract_inverted_index.duration | 263 |
| abstract_inverted_index.efficacy | 43 |
| abstract_inverted_index.enrolled | 140 |
| abstract_inverted_index.illness, | 259 |
| abstract_inverted_index.invasive | 63, 357 |
| abstract_inverted_index.isolates | 247 |
| abstract_inverted_index.outcomes | 59, 163, 333 |
| abstract_inverted_index.pathogen | 9 |
| abstract_inverted_index.patients | 61, 76, 87, 109, 180, 188, 192, 197, 335 |
| abstract_inverted_index.positive | 89, 115 |
| abstract_inverted_index.received | 67, 193 |
| abstract_inverted_index.severity | 257 |
| abstract_inverted_index.standard | 342 |
| abstract_inverted_index.surgical | 260 |
| abstract_inverted_index.syndrome | 224 |
| abstract_inverted_index.therapy, | 343 |
| abstract_inverted_index.Collected | 149 |
| abstract_inverted_index.LZD.Table | 70 |
| abstract_inverted_index.Linezolid | 80, 184 |
| abstract_inverted_index.Medtronic | 365 |
| abstract_inverted_index.Microsoft | 120 |
| abstract_inverted_index.admission | 146 |
| abstract_inverted_index.all-cause | 168, 294 |
| abstract_inverted_index.antitoxin | 25 |
| abstract_inverted_index.bacterial | 34 |
| abstract_inverted_index.comparing | 86 |
| abstract_inverted_index.determine | 353 |
| abstract_inverted_index.employee, | 370 |
| abstract_inverted_index.evaluated | 58 |
| abstract_inverted_index.excluded. | 148 |
| abstract_inverted_index.facility, | 326 |
| abstract_inverted_index.important | 8 |
| abstract_inverted_index.included: | 151 |
| abstract_inverted_index.included; | 190 |
| abstract_inverted_index.infection | 65, 153, 235 |
| abstract_inverted_index.linezolid | 18 |
| abstract_inverted_index.mortality | 169, 295 |
| abstract_inverted_index.prevalent | 238 |
| abstract_inverted_index.receiving | 77, 181 |
| abstract_inverted_index.syndromes | 74 |
| abstract_inverted_index.therapies | 178 |
| abstract_inverted_index.variables | 150 |
| abstract_inverted_index.(surgical, | 159 |
| abstract_inverted_index.2.Severity | 173 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 319 |
| abstract_inverted_index.adjunctive | 24, 177 |
| abstract_inverted_index.bacteremia | 226, 274 |
| abstract_inverted_index.consistent | 344 |
| abstract_inverted_index.difference | 255, 286, 331 |
| abstract_inverted_index.identified | 108 |
| abstract_inverted_index.incomplete | 137 |
| abstract_inverted_index.increasing | 48, 321 |
| abstract_inverted_index.infections | 31 |
| abstract_inverted_index.resistance | 323 |
| abstract_inverted_index.resistant. | 250 |
| abstract_inverted_index.synthesis. | 36 |
| abstract_inverted_index.therapies, | 136 |
| abstract_inverted_index.Clindamycin | 15, 78, 182 |
| abstract_inverted_index.Disclosures | 359 |
| abstract_inverted_index.bacteremia, | 131 |
| abstract_inverted_index.literature. | 347 |
| abstract_inverted_index.readmission | 288 |
| abstract_inverted_index.resistance, | 50 |
| abstract_inverted_index.significant | 254, 285, 330 |
| abstract_inverted_index.stockholder | 371 |
| abstract_inverted_index.accompanying | 225 |
| abstract_inverted_index.hospice/died | 142 |
| abstract_inverted_index.Retrospective | 83 |
| abstract_inverted_index.Streptococcus | 4 |
| abstract_inverted_index.demographics, | 152 |
| abstract_inverted_index.high-inoculum | 29 |
| abstract_inverted_index.microbiologic | 155 |
| abstract_inverted_index.polymicrobial | 130 |
| abstract_inverted_index.significantly | 276 |
| abstract_inverted_index.interventions, | 261 |
| abstract_inverted_index.1.Comorbidities | 71 |
| abstract_inverted_index.characteristics | 200 |
| abstract_inverted_index.characteristics, | 154 |
| abstract_inverted_index.immunoglobulin), | 160 |
| abstract_inverted_index.life-threatening | 13 |
| abstract_inverted_index.infection-related | 171 |
| abstract_inverted_index.readmission).Table | 172 |
| abstract_inverted_index.abscess/cellulitis; | 231 |
| abstract_inverted_index.Treatment-associated | 309 |
| abstract_inverted_index.(treatment-associated | 164 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| citation_normalized_percentile.value | 0.03504484 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |